Skip to main content
. 2021 Apr 22;11:630256. doi: 10.3389/fonc.2021.630256

Figure 2.

Figure 2

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) sequencing on tumor tissues of case 1. Wild type KRAS (top) and acquired KRAS mutations. (A) Wild type KRAS before treatment (top) and a KRAS Q61H mutation (bottom) after receiving Osimertinib. (B) Wild type KRAS before treatment (top) and a KRAS G12D mutation (bottom) after receiving Osimertinib.